Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease.

ABSTRACT:

Background and aims

Cystic Fibrosis associated liver disease (CFLD) develops in approximately 30% of CF patients. However, routine sensitive diagnostic tools for CFLD are lacking. Within this study, we aimed to identify new experimental biomarkers for the detection of CFLD.

Methods

45 CF patients were included in the study and received transient elastography. Differential regulation of 220 different serum proteins was assessed in a subgroup of patients with and without CFLD. Most interesting candidate proteins were further quantified and validated by ELISA in the whole patient cohort. To assess a potential relation of biomarker expression to the degree of hepatic fibrosis, serum biomarkers were further determined in 18 HCV patients where liver histology was available.

Res

SUBMITTER: Rath T 

PROVIDER: S-EPMC3597583 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature